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Accepted 6 April 2016Objective: To characterize healthcare costs, resource use, and treatment patterns of survey respondents with
a history of depression who are high utilizers (HUds) of healthcare and to identify factors associated with
high utilization.
Methods: Adults with two or more depression diagnoses identiﬁed from the HealthCore Integrated
Research Database were invited to participate in the CODE study, which links survey data with 12-month
retrospective claims data. Patient surveys provided data on demographics, general health, and symptoms
and/or comorbidities associated with depression. Similar clinical conditions also were identiﬁed from the
medical claims. Factors associated with high utilization were identiﬁed using logistic regression models.
Results: Of 3132 survey respondents, 1921were included, 193 of whomwere HUds (deﬁned as thosewho incurred the
top 10% of total all-cause costs in the preceding 12months).Mean total annual healthcare costswere eightfold greater for
HUds than for non-HUds ($US56,145 vs. $US6,954; p b .0001). HUds incurredmore inpatient encounters (p b .0001) and
emergency department (p=.01) and physician ofﬁce visits (p b .0001). Similar ﬁndings were observed for mental
healthcare costs/resource use. HUdswere prescribed twice asmanymedications (totalmean: 16.86 vs. 8.32; psychotropic
mean:4.11vs. 2.61;bothpb .0001).HUds reportedhigher levels ofdepression severity, fatigue, sleepdifﬁculties, pain, high
alcohol consumption, and anxiety. Predictors of becoming a HUd included substance use, obesity, cardiovascular disease,
comorbidity severity, psychiatric conditions other than depression, and pain.
Conclusion: Focusing on pain, substance use, and psychiatric conditions beyond depressionmay be effective approaches to
reducing high costs in patients with depression.
© 2016 Eli Lilly and Company. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Alcohol use1. Introduction
Healthcare decisionmakers are beginning to pay greater attention to
the relatively small group of high utilizers (HUs) who consume a
disproportionate amount of healthcare resources. For instance, using
Medicaid data, 5% of beneﬁciaries, termed ‘super-utilizers’, accounted
for 54% of total expenditure in 2008 [1].
Studies focusing on HUs frequently report an association between
high resource utilization, healthcare costs, and depression [2]. HUs
with depression or in partial remission were found to incur more ofﬁce
visits and days hospitalized than those without depression [3]. HU
populations have been used to evaluate the effectiveness of screening
programs and treatments for depression [4–6]. Von Korff et al. [7]
investigated the association between disability and depression among
HUs and concluded, “Depressed high utilizers of medical care are anand Company, Indianapolis, IN
lsevier Inc. This is an open access artiimportant group to study because they are often afﬂicted by severe
chronic medical conditions and account for a share of healthcare
resource consumption disproportionate to their numbers.” Depression
is also cited as a comorbidity in other high utilization populations,
including those with diabetes [8], spinal cord injury [9], advanced
cancer [10], chronic musculoskeletal pain [11], and post-traumatic stress
disorder [12]. Yet the relative impact of symptoms associated with de-
pression or other covariates on healthcare utilization and cost in HUs
has not been well studied. Potentially this is because data sources with
quality cost data, such as administrative claims, lack clinical severity infor-
mation, and comprehensive cost data are challenging to collect longitudi-
nally in survey research.
Unlike most previous studies of high utilization [2,3,13], which in-
cluded heterogeneous populations andwere conducted retrospectively,
in the current study we adapted the general deﬁnition of HUs by focus-
ing on utilization in a subpopulation of HUs with depression (HUd),
using a retrospective/prospective design. A HUd is deﬁned in this
study as a person with depression whose all-cause total costs place
him/her in the top decile of this study's cost distribution.cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tics, and outcomes among survey respondents who are HUds and
compare them with non-HUds using administrative claims. Using total
costs allows for a comprehensive deﬁnition of HUds along multiple di-
mensions of healthcare resources. The study also seeks to determine
factors affecting high utilization.
2. Methods
The data reported here are from the CO-morbidities and Symptoms
of DEpression (CODE) study, which utilized a retrospective/prospective
ﬁxed-cohort repeated-measures design in which initial and 6-month
patient survey data were linked to 24 months of administrative
claims data (±12 months from the initial survey date). The source
for the claims data was the HealthCore Integrated Research Database
(HIRD),which containsmedical, pharmacy, and enrollment information
for patients from a large commercially insured population from 14
geographically-diverse US health plans. Medical data are collected
from physician and facility claims (containing diagnoses and
procedure codes) and are integrated with outpatient pharmacy
claims (captured by national drug codes) for all plan members.Fig. 1. Derivation of ﬁnCoverage includes health maintenance organizations, point of
service, preferred provider organizations, and fee-for-service plans.
A central institutional review board approved the CODE protocol
and all survey-related materials. All patient data were handled in
compliance with US Health Insurance Portability and Accountability
Act of 1996 regulations.
The CODE survey sample was identiﬁed from medical claims in the
HIRD from 1 June 2009 through 31 May 2010 and comprised patients
with at least two distinct medical claims with a primary diagnosis
code for depression using the International Classiﬁcation of Diseases,
9th Revision, Clinical Modiﬁcation (ICD-9-CM) (Appendix A) (Fig. 1).
Eligible patients were aged 18–64 years and continuously enrolled in
their health plan for ≥12 months with both medical and pharmacy
beneﬁts. Patients with at least one medical claim during the study
period for bipolar disorder or schizophrenia were ineligible.
Survey recruitment (1 January 2011 through 9 February 2011) ended
when the target enrollment goal of at least 3000 patients was attained.
Eligible patients were mailed invitations to participate, along with a
study description. Patients could call directly or wait to be contacted to
opt in or out of the study. Once verbal informed consent was received,
respondents were screened for further eligibility and offered the optional study cohorts.
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the internet. Patients were considered unavailable after six contact
attempts. The survey required approximately 30 min, and
respondents were compensated $US35 for their time. After
survey completion, respondents' survey and claims data were
linked. No major differences in demographic characteristics be-
tween full respondents (completed initial and six-month surveys)
and partial respondents (completed only initial survey) were ap-
parent (data not shown).
The current analysis utilizes data from the initial survey for respon-
dents with non-missing depression and anxiety survey scores and
complete medical and pharmacy claims (n=1921; 61.3% of the initial
3132 survey respondents) (Fig. 1).
Groups of interest were established based on the distribution of all-
cause total costs in the 12 months prior to the survey date. Patients in
the top 10% of costs were identiﬁed as HUds andwere evaluated against
the remaining participants (non-HUds).Table 1
Annual costs for depressed patients: high utilizers of healthcare with depression (HUds)
vs. non-HUds.
Annual healthcare costs HUds Non-HUds P-value
n=193 n=1728
All-cause
Total medical 45,436 (± 42,002) 4,322 (± 4456) b .0001
Inpatient 19,144 (± 26,672) 446 (± 2068) b .0001
Emergency department 1,856 (± 7237) 307 (± 1085) 0.0034
Physician ofﬁce 4,574 (± 5900) 1,557 (± 1537) b .0001
Primary care physician 933 (± 3524) 300 (± 432) 0.0135
Psychiatrist 303 (± 820) 236 (± 717) 0.2778
Non-physician 772 (± 1601) 474 (± 1032) 0.0124
Others (incl. missing,
unknown)
2,567 (± 4442) 546 (± 928) b .0001
Outpatient 19,603 (± 31,033) 2,013 (± 2983) b .0001
Pharmacy 10,709 (± 11,371) 2,632 (± 3013) b .0001
Total 56,145 (± 40,886) 6,954 (± 5649) b .0001
Mental health related
Total medical 12,943 (± 19,838) 1,377 (± 2092) b .0001
Inpatient 7,663 (± 14,753) 209 (± 1274) b .0001
Emergency department 511 (± 2216) 65 (± 430) 0.0058
Physician ofﬁce 1,468 (± 2752) 898 (± 1328) 0.0050
Primary care physician 242 (± 2169) 77 (± 305) 0.2919
Psychiatrist 301 (± 819) 235 (± 716) 0.2811
Non-physician 649 (± 1566) 441 (± 1028) 0.0733
Others (incl. missing,
unknown)
275 (± 813) 145 (± 537) 0.0310
Outpatient 3,177 (± 11,434) 205 (± 818) 0.0004
Outpatient psychiatric
servicesa
1,198 (± 7905) 97 (± 447) 0.0545
Pharmacy 2,671 (± 3488) 1,238 (± 1845) b .0001
Total 15,614 (± 20,651) 2,615 (± 2922) b .0001
Data are presented as mean ± standard deviation unless otherwise indicated.
a Includes psychiatric diagnostic evaluation, psychotherapy (individual, group, family),
psychiatric services or procedures (including pharmacotherapy, narcosynthesis,
biofeedback training, hypnotherapy, electroconvulsive therapy, etc.), suicide risk
assessment, psychiatric treatment (home visit).2.1. Measures
The CODE survey collected respondent information on demo-
graphics, general health, and the presence and severity of depression
aswell as symptomsand/or comorbidities often associatedwith depres-
sion, including pain, fatigue, anxiety, sleep difﬁculty, and heavy alcohol
use (Appendix B). Demographics included race and ethnicity, body
mass index (BMI), marital status, education, employment status, and
family income level. General health was measured using the 12-item
General Health Questionnaire (GHQ-12) (range 0–36) [14] and through
lifestylemeasures of smoking status, diet (poor to healthy), activity, and
sexual functioning.
Variables of interest from the administrative claims data were spec-
iﬁed for the 12-month period prior to the survey date. Demographic
variables available from the claims included sex, age, geographic region
of residence, and insurance plan type.
Provider specialty (primary care physician [family or general
practitioner, internal medicine physician, or obstetrician/gynecologist],
psychiatrist, non-physician, and other/unknown/missing) was deﬁned
based on pre-period medical claims for the primary depression
diagnosis when available or by the prescriber specialty of the most
recent antidepressant prescription ﬁll.
Clinical conditions, including depressive disorders, anxiety,
fatigue/sleep-related conditions, pain disorders, alcohol use disor-
ders, other substance use conditions, sexual dysfunction, memory
loss, other psychiatric conditions, diabetes, cardiovascular disease,
thyroid disorders, obesity, cancer, and cerebrovascular disease,
were derived from the presence of ICD-9-CM diagnosis codes
(Appendix A) in any medical inpatient or outpatient or emergency
department claim. Mental health-related utilization and costs were
based on claims that contained ICD-9-CM and CPT codes in any posi-
tion that were related to mental health (Appendix C). Comorbidity
severity was measured using the Quan-Charlson Comorbidity Index
(QCI) [23].
Healthcare resource utilization and costs (inﬂation-adjusted to
$US, year 2012 values) were categorized based on the presence of
claims for each medical component (inpatient hospitalizations, ED
visits, physician ofﬁce visits, other outpatient visits) and pharmacy.
Overall all-cause healthcare utilization and costs as well as mental
health-related utilization and costs are reported. Any use of select
psychotropic medications was identiﬁed using standard measures
of adherence. Length of therapy (LOT) was deﬁned as the number
of days with the presence of a medication prescription ﬁll and was
capped at 365 days. The medication possession ratio (MPR) was
deﬁned as LOT divided by 365 days (i.e. length of the 12-month
period of interest). An MPR ≥80% is typically deemed a good indication
of adherence [24].2.2. Statistics
Cohort characteristics were summarized and compared using
chi-squared or Fisher's exact tests for categorical variables and t-tests
for continuous variables. Cost variables were compared using
Wilcoxon–Mann–Whitney tests to account for distribution skewness.
The conclusions were the same; therefore, t-test results are reported
for consistency. Two-sided 0.05 signiﬁcance levels were used without
multiplicity adjustment due to the nature of this exploratory study.
Logistic regression modeling was used to assess the relationship be-
tween patient factors, including symptoms associated with depression
and the likelihood of being a HUd. Development of the primary model
was guided by our objective to illuminate associations with survey-
speciﬁc measures. Therefore, utilization and cost variables, as well as
claims-based variables with domains that overlapped those of survey-
based variables, were excluded from the primary model. Additional
models were explored that 1) used stepwise model selection rather
than a manually selected model; 2) included additional claims-based
variables; 3) dichotomized continuous measures for simplicity; and
4) included interactions between measures of depression (16-Item
Quick Inventory of Depressive Symptomatology [QIDS]) and anxiety
[Generalized Anxiety Disorder scale [GAD-7]). Goodness of ﬁt was
assessed using the Akaike information criterion [25], c statistics [26],
and the Hosmer-Lemeshow test [26]. Odds ratios (ORs) and 95% conﬁ-
dence intervals were computed for all covariates in the ﬁnal model.3. Results
Of the 1921 study patients, 193 (10%) were classiﬁed as HUds and
1728 (90%) as non-HUds.
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Costs were signiﬁcantly higher for HUds than for non-HUds across
all medical and pharmacy cost components. An eightfold difference in
total annual healthcare costs (medical plus pharmacy) was found be-
tween HUds and non-HUds (Table 1). Total medical annual healthcare
costs (excluding pharmacy) were tenfold higher in HUds than in non-
HUds. Inpatient and outpatient encounters each accounted for approxi-
mately 40% of costs for HUds. Inpatient costs were 40-fold higher in the
HUd group than in the non-HUd group, and other disparities between
the two groups were seen for costs related to outpatient visits (tenfold
higher) and pharmacy (fourfold higher). Total mental health-related
costs were also sixfold higher in HUds, with a ninefold disparity inmed-
ical mental health-related annual costs.
3.2. Resource utilization
Table 2 illustrates the disparities in resource utilization between the
two cohorts. For example, the 60% rate of inpatient encounters for HUds
was approximately ninefold higher than the 6.6% rate for non-HUdsTable 2
Resource utilization and treatment for depressed patients: high utilizers of healthcare
with depression (HUds) vs. non-HUds.
Resource utilization HUds
n=193
Non-HUds
n=1728
P-value
All-cause utilization
Any inpatient encounters 116 (60.1) 114 (6.6) b .0001
Length of stay of those with
hospitalizations
10.24 (± 11.96) 4.07 (± 5.24) b .0001
Length of stay of total population 6.16 (± 10.53) 0.27 (± 1.68) b .0001
Any emergency department visits 76 (39.38) 291 (16.84) b .0001
# of emergency department visits 1.09 (± 4.56) 0.22 (± 0.63) 0.01
Any physician ofﬁce visits 192 (99.48) 1711 (99.02) 1.0000
# of physician ofﬁce visits 27.8 (± 23.45) 14.98 (± 13.84) b .0001
Any other outpatient visits 193 (100) 1,596 (92.36) b .0001
# of other outpatient visits 27.91 (± 20.09) 8.39 (± 9.85) b .0001
Mental health-related utilization
Any inpatient encounters 75 (38.86) 66 (3.82) b .0001
Length of stay of those with
hospitalizations
11.16 (± 12.95) 4.85 (± 6.53) 0.0003
Length of stay of total population 4.34 (± 9.72) 0.19 (± 1.57) b .0001
Any emergency department visits 36 (18.65) 84 (4.86) b .0001
# of emergency department visits 0.38 (± 1.78) 0.05 (± 0.25) 0.0120
Any physician ofﬁce visits 172 (89.12) 1,551 (89.76) 0.7823
# of physician ofﬁce visits 13.6 (± 21.66) 9.8 (± 12.93) 0.0177
Any other outpatient visits 104 (53.89) 584 (33.8) b .0001
# of other outpatient visits 4.54 (± 11.28) 1.06 (± 3.35) b .0001
Any outpatient psychiatric services 70 (36.27) 411 (23.78) 0.0001
# of visits involving outpatient
psychiatric services
2.9 (± 8.51) 0.79 (± 2.87) 0.0008
Medication utilization
Antidepressants
Any antidepressant
Selective serotonin reuptake
inhibitors
92 (47.67) 864 (50) 0.5389
Serotonin-norepinephrine
reuptake inhibitors
81 (41.97) 421 (24.36) b .0001
Bupropion 54 (27.98) 426 (24.65) 0.3114
Tricyclics 26 (13.47) 90 (5.21) b .0001
Other antidepressants 52 (26.94) 293 (16.96) 0.0006
Second generation antipsychotic
utilization
55 (28.5) 174 (10.07) b .0001
Second generation antipsychotic +
antidepressant
52 (26.94) 154 (8.91) b .0001
Mood-stabilizing anticonvulsants 5 (2.59) 19 (1.1) 0.0851
Lithium 3 (1.55) 16 (0.93) 0.4292
Hypnotics/sedatives 62 (32.12) 313 (18.11) b .0001
Any benzodiazepine 109 (56.48) 662 (38.31) 0.0005
Anxiolytics 119 (61.66) 734 (42.48) b .0001
Any antidepressant + benzodiazepine 85 (44.04) 487 (28.18) b .0001
Data are presented as n (%) or mean ± standard deviation.(p b .0001). HUds made more visits to the ED, physician ofﬁces, and
any other outpatient site.
Results were similar for mental health-related resource utilization,
with HUds havingmore inpatient encounters, ED visits, physician ofﬁce
visits, other outpatient visits, and outpatient psychiatric service visits.
Among those with inpatient encounters, HUds were hospitalized for
twice as long as non-HUds.
HUds were generally prescribed more psychotropic (mean
number of drugs: 4.11 ± 2.67 vs. 2.61 ± 1.74, p b .0001) and total
medications (mean number: 16.86 ± 7.97 vs. 8.32 ± 5.42,
p b .0001) than non-HUds. HUds were prescribed more tricyclic
antidepressants, serotonin-norepinephrine reuptake inhibitors, and
other antidepressants, whereas both groups used selective serotonin
reuptake inhibitors and bupropion to a similar extent. Antidepressant
exposure was longer (mean LOT 275.52 ± 84.03 days vs. 249.33 ±
97.22 days, p=.0003) and adherence was greater (50.26% vs. 37.15%,
p=.0029) among HUds.
HUds were more likely to be prescribed second-generation
antipsychotics, hypnotics/sedatives, anxiolytics, and benzodiaze-
pines (Table 2), including short/intermediate-acting (p=.0064) or
long-acting (p b .0001) formulations; no differences in usage were
observed between groups for mood-stabilizing anticonvulsants or
lithium. HUds also were prescribed more medicine combinations
than non-HUds, including co-administration of an antidepressant
with a second-generation antipsychotic or benzodiazepine.
3.3. Demographic and clinical characteristics
HUds and non-HUds shared some similar demographic characteris-
tics (Table 3). More than three-quarters of respondents in both groups
were female. Most were middle aged (45–64 years), although HUds
were signiﬁcantly older on average than non-HUds. More than 90% of
both groups were Caucasian/White and most were married, had a sig-
niﬁcant other or domestic partner, or were living with another person.
A signiﬁcant difference in geographic region was observed, with HUds
being more likely to live in the Northeast and West regions than non-
HUds. HUds were less likely to be employed full-time and more likely
to be disabled, retired, or unemployed. Educational status and family
income were similar for both groups. Additionally, a greater proportion
of HUds were seeing primary care physicians or psychiatrists than
non-HUds, whereas non-HUds were more likely to be treated by
non-physicians.
Clinical differences were apparent between the two groups
(Table 4). HUds hadmore severe depression than non-HUds, as indicat-
ed by signiﬁcantly higher mean scores on the QIDS-self-report
HUds reported higher levels of fatigue than non-HUds, with
increased scores on the mean Fatigue Associated with Depression
Questionnaire (FAsD) total, impact, and experience subscales. Sleep
difﬁculties were also more common in HUds, as indicated by higher
scores on the Athens Insomnia Scale (AIS). Similar trends were
found in the claims data, with HUds also more likely to have
fatigue/sleep-related diagnoses.
GAD-7 patient-reported anxiety severity levels were elevated in
HUds compared with non-HUds (Table 4), as was the percentage of
patients with claims for anxiety (67.88% vs. 60.07%, p=0.0351). Yet,
the presence of diagnoses of GAD (HUd vs. non-HUd: 15.03% vs.
11.17%, p=.1119), post-traumatic stress disorder (4.15% vs. 2.72%,
p=.2602) or other anxiety disorders (37.31 vs. 36.57%, p=.8414)
from the claims did not differ between groups.
Mean pain severity as measured by Brief Pain Inventory (BPI)
was higher in HUds, and more than 92% of HUds had claims for pain
disorders compared with 59% of non-HUds (p b .0001).
HUds had poorer self-reported general health, based on higher
GHQ-12 scores, and more comorbidity, as indicated by higher mean
QCI scores. Previous diagnoses of diabetes, cardiovascular disease,
thyroid disorders, cancer, cerebrovascular disease, memory loss,
Table 3
Demographics: high utilizers of healthcare with depression (HUds) vs. non-HUds.
HUds Non-HUds P-value
n=193 n=1728
Female 149 (77.2) 1333 (77.14) 0.9838
Age (years) 49.27 (± 11) 46.18 (± 11.65) 0.0004
Geographic region 0.0383
Northeast 38 (19.69) 264 (15.28)
South 31 (16.06) 410 (23.73)
Midwest 48 (24.87) 491 (28.41)
West 74 (38.34) 541 (31.31)
Unknown 2 (1.04) 22 (1.27)
Health plan type
Health Maintenance
Organization/Point of Service
32 (16.58) 430 (24.88)
Preferred Provider Organization 125 (64.77) 1071 (61.98)
Others 36 (18.65) 227 (13.14) 0.0004
Race and ethnicity 0.3700
Caucasian/white 179 (92.75) 1569 (90.8)
Others 14 (7.25) 159 (9.2)
Marital status 0.0105
Married or partnered 113 (58.55) 986 (57.06)
Single, separated, divorced
or widowed
77 (39.9) 740 (42.82)
Others 3 (1.55) 2 (0.12)
Educational status 0.1044
High school or less 39 (20.21) 294 (17.01)
College 117 (60.62) 1032 (59.72)
Graduate 36 (18.65) 401 (23.21)
Other 1 (0.52) 1 (0.06)
Employment status b0.0001
Employed full-time 51 (26.42) 847 (49.02)
Employed part-time or self 46 (23.83) 343 (19.85)
Homemaker 23 (11.92) 192 (11.11)
Student 2 (1.04) 54 (3.13)
Disabled, retired, unemployed 71 (36.79) 292 (16.9)
Family income 0.5076
Less than $25,000 25 (12.95) 214 (12.38)
$25,000–$99,999 109 (56.48) 1017 (58.85)
$100,000 and greater 40 (20.73) 377 (21.82)
Don't know/refused 19 (9.84) 120 (6.94)
Most recent antidepressant
prescribing/treating physician
specialty
0.0227
Primary care physician 73 (37.82) 616 (35.65)
Psychiatrist 74 (38.34) 622 (36.00)
Non-physician 21 (10.88) 268 (15.51)
Others 8 (4.15) 25 (1.45)
Missing/unknown 17 (8.81) 197 (11.40)
Data are presented as n (%) or mean ± standard deviation.
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Although a previous diagnosis of obesity was three times more
common in HUds than in non-HUds, no between-group difference
in mean BMI was observed.
ThemeanAlcohol Consumption Scale scorewas higher in HUds than
in non-HUds. No between-group difference was observed in the
percentage of heavy drinkers; however, these data were missing for
more HUds than non-HUds (30.6% vs. 22.1%; p=.008). HUds were
more likely to have diagnoses for alcohol use disorders or dependence
or other substance use conditions.
For lifestyle factors, a decline in normal activity levels and change in
sexual functioningwere reportedmore frequently in HUds than in non-
HUds. However, no between-group differences were found in smoking
or having a fair/poor diet.
3.4. Factors associated with being a HUd
Several factors associated with being a HUd were identiﬁed.
Of the primary conditions of interest (self-reported symptoms from
the survey), only pain (p=.0037) was found to be associated withbeing a HUd. Clinically signiﬁcant levels of depression (as indicated by
moderate QIDS scores), anxiety, fatigue, sleep disruption, or general
health were not associated when considering all factors.
Respondents with pain were almost 74% more likely to be HUds,
where “presence of pain” was deﬁned as scores ≥4 on the 1–10
scale. In an alternative model, where the full pain score range was
used as a covariate, a one-point increase on the scale was associated
with a 13.7% increased chance of being a HUd (p=.0385). Both
approaches suggest a marked association between pain and increased
healthcare costs.
Fig. 2 shows the strongest associationwas a ‘use of other substances’
diagnosis; individuals falling into this category hadmore than a ﬁvefold
increased risk of being aHUd. HUdswere also associatedwith havingdi-
agnoses of obesity, cardiovascular disease, high comorbidity severity,
other psychiatric conditions, and pain. Diagnoses of sexual dysfunction
or memory loss or medical conditions such as cancer, cerebrovascular
disease, or thyroid dysfunction were not associated with being a HUd
when all other factors were considered.
Several factors present at the initial assessment were associated
with less risk of being a HUd (Fig. 2). These included holding a full-
time job, having diabetes, and being from Mid-Western or Southern
US regions. The effects of sex, age, marital status, or higher education
were not signiﬁcant.
Model goodness of ﬁt and signiﬁcance of survey-based associated
factors did not differ between models where factors were chosen man-
ually comparedwithmodels chosen via automatic stepwise selection or
when dichotomous or continuous variables were used. No statistically
signiﬁcant relationship was observed between depression and anxiety
when interaction terms were included.
4. Discussion
In a cohort of patients with a history of depression identiﬁed from a
large administrative claims database with self-reported depression
ratings and linked survey and administrative claims data, costs and
resource utilization for HUds (whose all-cause total costs fell within
the top decile of cost distribution), were compared with ﬁndings for
non-HUds. Mean total healthcare costs for HUds were eightfold higher
than those for non-HUds, with higher expenditures attributed to more
inpatient stays, outpatient encounters, ED use, and physician visits.
Similar ﬁndings were found for mental healthcare, with a sixfold
increase in total costs among HUds. HUds used twice as many medica-
tions as non-HUds, including more prescriptions for psychotropic
medications, serotonin–norepinephrine reuptake inhibitors, tricy-
clic antidepressants, second-generation antipsychotics, hypnotics/
sedatives, benzodiazepines, and anxiolytics.
We examined the data to see whether characteristics other than
healthcare utilization levels distinguished HUds from non-HUds. We
found patients with a history of depression in the CODE study who
became HUds tended to be older, less likely to be employed full time,
and more likely to be disabled, retired, or unemployed. They were also
more likely to be residents of Northeastern or Western US regions
than non-HUs. Univariate analyses showed that the higher healthcare
utilization of these patients was associated with a range of characteris-
tics, including more severe depression, fatigue, anxiety, pain, memory
loss, other psychiatric conditions, or sleep difﬁculties, as well as
comorbidities such as obesity, diabetes, cardiovascular disease, thyroid
disorders, cancer, and cerebrovascular disease. HUds were more likely
to use or be dependent upon alcohol or other substances, although
the presence of heavy drinking was not found to be a signiﬁcant
determinant. Smoking or maintaining a poor diet did not portend high
utilization, although declines in normal activity levels and changes in
sexual functioning were more common in HUds.
Multivariate analyses were performed to identify covariates of
depression that were indicative of future high utilization. Using a
logistic regression model, the strongest predictor of becoming a HUd
Table 4
Clinical characteristics, comorbidities, lifestyle, and wellness variables at initial assess-
ment: high utilizers of healthcare with depression (HUds) vs. non-HUds.
Clinical characteristics HUds Non-HUds P-value
n=193 n=1728
Depression severity (QIDS-SR score) 10.23 (± 5.68) 8.73 (± 4.79) 0.0005
Clinically signiﬁcant depression— yes 144 (74.61) 1,221 (70.66) 0.2509
Fatigue
FAsD experience subscale 3.13 (± 1.03) 2.77 (± 0.97) b .0001
FAsD experience — yes 91 (47.15) 537 (31.08) b .0001
FAsD impact subscale 2.69 (± 1.1) 2.37 (± 1.01) b .0001
FAsD total score 2.92 (± 0.99) 2.59 (± 0.91) b .0001
Average 24 hour pain score (BPI) 3.72 (±2.56) 2.46 (± 2.41) b .0001
Clinically signiﬁcant pain — yes 109 (56.48) 577 (33.39) b .0001
Sleep disruption (AIS) 8.44 (± 4.85) 7.16 (± 4.62) 0.0003
Clinically signiﬁcant sleep
disruption — yes
130 (67.36) 1,046 (60.53) 0.0649
Anxiety (GAD-7) 7.98 (± 5.71) 7.04 (± 5.41) 0.0233
Clinically signiﬁcant GAD — yes 93 (48.19) 679 (39.29) 0.0169
Alcohol Consumption Scalea 10.1 (± 1.96) 9.37 (± 2.36) b0.0001
Heavy drinking — yesb 12 (6.22) 125 (7.23) 0.6029
General health (GHQ-12) 16.01 (± 7.38) 14.15 (± 6.37) 0.0009
QCI comorbid score 1.85 (± 2.36) 0.4 (± 0.87) b .0001
Diagnoses
Alcohol use or dependence 11 (5.7) 38 (2.2) 0.0075
Other substance use conditions 18 (9.33) 32 (1.85) b .0001
Sexual dysfunction, erectile
dysfunction
4 (2.07) 11 (0.64) 0.0556
Memory loss 6 (3.11) 13 (0.75) 0.0084
Other psychiatric conditions 55 (28.5) 299 (17.3) 0.0001
Fatigue/Sleep-related diagnosesc 112 (58.03) 558 (32.29) b .0001
Pain disorders 178 (92.23) 1024 (59.26) b .0001
Diabetes mellitus 39 (20.21) 168 (9.72) b .0001
Cardiovascular disease 33 (17.1) 60 (3.47) b .0001
Thyroid disorders 56 (29.02) 293 (16.96) b .0001
Obesity 35 (18.13) 111 (6.42) b .0001
Cancer 29 (15.03) 54 (3.13) b .0001
Cerebrovascular disease 18 (9.33) 30 (1.74) b .0001
Lifestyle and wellness variables
Current smoker 25 (12.95) 224 (12.96) 0.9970
Fair/poor diet 60 (31.09) 521 (30.15) 0.7880
Decrease in normal activity levels 116 (60.1) 706 (40.86) b .0001
Change (+/-) in sexual functioning 73 (37.82) 516 (29.86) 0.0203
BMI 28.07 (± 6.37) 28.36 (± 7.25) 0.5564
Data are presented as n (%) or mean ± standard deviation.
AIS = Athens Insomnia Scale; BPI = Brief Pain Inventory; BMI = Body Mass Index;
FAsD=FatigueAssociatedwith Depression Questionnaire; GAD-7=GeneralizedAnxiety
Disorder scale; GHQ=General Health Questionnaire; QCI = Quan-Charlson Comorbidity
Index; QIDS-SR = Quick Inventory of Depressive Symptomatology (Self-Report).
a Alcohol Consumption Scale scores were available for 134 (69.43%) of HUds and 1347
(77.95%) of non-HUds.
b Heavy drinking was assessed with the Alcohol Consumption Scale and deﬁned as ≥5
alcoholic drinks formales and ≥4 alcoholic drinks for females in a single day [22]. Note that
these data were missing for more HUds than non-HUds (30.6% vs. 22.1%; p=.008).
c Fatigue/sleep related diagnoses included any claims for chronic fatigue syndrome, gen-
eral fatigue symptoms, anemia, insomnia, hypersomnia, and other sleep disturbances.
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disease, comorbidity severity, other psychiatric conditions, and pain.
Using this adjustedmodel,moderate depression, anxiety, fatigue, sexual
dysfunction, memory loss, sleep disturbance, and general health were
not associated with becoming a HUd.
Interestingly, ﬁndings from the model suggested that several
variables were associated with less risk of becoming a HUd, including
holding a full-time job, having diabetes, and living in the mid-western
or southern US. Serious medical conditions, including cancer and
cerebrovascular disease, were not associated with being a HUd. The im-
pact of some of these clinical conditionsmay bemodiﬁed due to overlap
with the QCI comorbidity index, obesity, and/or their relatively low
prevalence in this cohort.
These ﬁndings are similar in part to a comprehensive literature re-
view that reported all non-genetic factors predictive of or associatedwith response to depression therapy [27]. In that study, anxiety and
pain contributed to worse antidepressant treatment outcomes. In the
STAR*D study, comorbid anxiety was associated with poorer response
to depression treatment, as well as increased rates of adverse events,
psychiatric hospitalizations, and suicide attempts [28].
Two studies evaluated the impact of substance abuse on treat-
ment response and found mixed results. In a large case study of
over 4000 patients, comorbid substance abuse increased the risk of
depression relapse and recurrence [29], whereas in a randomized
clinical trial of over 600 patients with chronic depression or double
depression, neither substance abuse nor anxiety was associated
with treatment response [30].
In a previous analysis of CODE study data, one-third of patients with
survey and complete claims data had signiﬁcant levels of fatigue [31].
Patients with fatigue incurred higher total healthcare costs, used more
healthcare resources, and reported increased severity of depression,
pain, sleep difﬁculty, and anxiety. The current results suggest that al-
though fatigue is an important covariate of depression and ismore com-
mon in HUds, its presence may not be predictive of becoming a HUd.
Our results suggest that an effective approach to reduce the likeli-
hood of patients with depression becoming HUds, thereby reducing
high healthcare utilization and the resulting costs, would be to focus
on several speciﬁc and modiﬁable patient characteristics, such as the
use of other substances, pain, and the presence of psychiatric conditions
other than depression. Obesity, cardiovascular disease, and comorbidity
severity appear to be other red ﬂags for future high healthcare utiliza-
tion and may also be good targets for early and effective intervention.
4.1. Limitations
Several limitations should be considered when interpreting these
ﬁndings. The prospective/retrospective hybrid study design offers an ef-
ﬁcient and effective method to examine outcomes by augmenting sur-
vey data with administrative claims data; however, typical limitations
of prospective and retrospective observational research are present.
Self-reported symptoms were assessed at a single time point, whereas
costs were observed over 12 months preceding the survey; hence, the
association between symptoms and costs may differ with alternative
time periods. Claims data are collected for the purpose of payment
and not for research. Medication use identiﬁes that prescriptions were
ﬁlled but lacks information on whether the drug was ingested or if ad-
ditional medications were taken, including over-the-counter drugs,
drugs paid for by the individual, or drugs provided through ofﬁce sam-
ples. Medical diagnostic codes, including those for comorbid medical
conditions, may be incorrectly coded, undercoded, incomplete, or in-
cluded as rule-out criteria. This is especially true with depression,
which has been known to be under-reported in claims [32]. Participants
were identiﬁed as having at least two distinctmedical claims for depres-
sion in a large US commercial database, rather than through structured
diagnostic interviews. However, respondents answered a self-reported
question regarding whether they had been told by a physician that
they had depression, and completed the QIDS-SR, which has been
shown to correlate strongly with the HAM-D and other clinician-rated
scales [16]. Nevertheless, our depression identiﬁcation algorithm has
not been validated. In addition, survey results were based on respon-
dents' self-report and could not be independently veriﬁed through clin-
ical documentation; thus, their accuracy may be subject to self-report
and recall biases. Although nomajor differences in demographic charac-
teristics between full respondents and partial respondents were identi-
ﬁed in the limited data available from the claim forms, differences
beyond the data collectedmay have existed; it was not, however, possi-
ble to quantify this. It is also possible that individuals with other diagno-
ses, such as primary psychotic disorders, were included in the study. As
patients were identiﬁed based on prior claims, the duration and course
of depression was variable. In some cases, patients reported no symp-
toms of depression during the survey. Participants therefore included
Fig. 2. Factors associated with being a high utilizer of healthcare in depressed patients. Abbreviations: QCI: Quan–Charlson Comorbidity Index; QIDS: 16-item Quick Inventory of
Depressive Symptomatology aUse of other substances diagnoses primarily refers to the use of drugs other than alcohol, including Schedule I and Schedule II drugs (codes V65.42
[counseling on substance use and abuse], 977.9 [unspeciﬁed drug or medical substance], and 304.xx [drug dependence]). bOther psychiatric conditions diagnoses refer to conditions
other than depression, including manic disorders and psychosis. cPresence of pain deﬁned as scores ≥4 on the 1–10 scale.
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possibly, those who were incorrectly diagnosed. Importantly, the
study was limited to the determination of the resource utilization
and direct costs of care of HUds, and may not be generalizable to all
HUs of healthcare. Since only individuals and/or their dependents
with employer-provided commercial health insurance were included,
the results may not generalize to other populations such as uninsured
individuals, Medicaid or Medicare recipients, or individuals in
non-US countries with alternative healthcare systems. In addition,
the population includes a predominance of Caucasians compared to
the general US population; hence, the study does not purport to pro-
vide insights into the potential contribution of race or ethnicity to
outcomes. Information not available in claims data or through self-
report could impact study outcomes, such as certain clinical and
disease-speciﬁc parameters.
Costs were detailed from a payers' perspective and do not include
the entire cost of depression [33,34]. For the regressionmodel, the sam-
ple size was too small to replicate in test samples.
5. Conclusions
Not all depressed patients will become HUds of healthcare.
The results of this unique prospective/retrospective hybrid study
design conﬁrm that residual symptoms of depression or speciﬁc
comorbidities add to the economic burden of illness and highlight
the importance of treating patients to full resolution of all depression
symptoms. HUds have more severe depression symptoms, and are
more likely to manifest fatigue, sleep disturbance, anxiety, pain, sub-
stance use, and have certain comorbidities than non-HUds. However,
our results suggest only some of these variables (e.g. use of other
substances, obesity, cardiovascular disease, comorbidity burden,other psychiatric illnesses other than depression, and pain) may be
associated with becoming a HUd. Until genotypic differentiation
can adequately distinguish subgroups in understanding the relation-
ship between depression and healthcare costs, identiﬁcation of fac-
tors associated with high utilization may help focus therapeutic
efforts to mitigate high healthcare utilization and costs in depressed
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D
A
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D
C
T
O
C
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Fa
A
In
PICD-9-CM codesHsychiatric conditions
epression 296.2x, 296.3x, 300.4x
lcohol use disorders or dependence 303.xx, 305.0x
ther substance use conditions V65.42, 977.9, 304.xx
xual dysfunction, Erectile
dysfunction799.81, 302.71, 302.72emory loss 780.93
ipolar disorder 296.0x, 296.1x or 296.4x-296.9x
hizophrenia 295.xx
ther psychiatric conditions 290.xx to 316.xx, V40.x, excluding the
following: 295.0x to 295.9x, 299.0x,
299.9x, 302.6x, 307.59, 309.83, 312.1x,
312.2x, 312.81, 312.9x, 313.xx, 314.9x,
315.35; 296.xx, 298.xx, 300.xx, 302.71,
303.xx to 305.xx, 309.0x, 309.1x, 311.xx,
309.81tigue/Sleep Related Diagnoses
(including chronic fatigue syndrome,
general fatigue symptoms, anemia,
insomnia, hypersomnia, other sleep
disturbance)780.71, 780.70, 780.79, 300.5x, 280.xx to
284.xx, 780.51, 780.52, 307.41, 307.42,
327.0x, 780.53, 780.54, 307.43, 307.44,
327.1x, 327.20 to 327.23, 327.29, 327.3x
to 327.8x, 780.50, 780.55 to 780.59, 786.03ain disorders (including back pain,
ﬁbromyalgia, and other pain)P
A720.xx, 721.2x to 721.9x, 722.1x to
722.3x, 722.5x, 722.6x, 722.70, 722.72,
722.73, 722.80, 722.82, 722.83, 722.90,
722.92, 722.93, 724.xx, 729.1x, 780.96,
338.xx, 307.80, 053.1x, 250.6x, 307.8x,
323.xx, 335.20, 335.34, 336.9x, 337.1x,
337.2x, 338.3x, 339.xx, 340.xx, 341.xx,
346.0x to 346.9x, 350.xx, 351.xx, 353.xx
to 356.xx, 357.2x, 358.xx, 524.6x, 577.1x,
696.xx, 714.xx, 715.xx, 719.xx, 720.xx,
721.0x to 722.4x, 722.71, 722.81, 722.91,
723.1x, 724.4x, 728.0x, 729.0x, 729.2x,
729.5x, 784.0x, 786.5x, 789.xx, 733.99,
733.14, 780.71, 820.8x, 820.9x, 951.4x,
952.xx, 953.4x, 955.5x to 955.7x;
Procedure code: 88.81omorbidities
iabetes mellitus 250.xx
ardiovascular disease 410.xx to 414.xx, 440.xx, 441.xx, 443.9x
hyroid disorders 241.xx to 246.xx
besity 278.0x, V85.3, V85.4
ancer 140.xx to 172.xx, 174.xx to 208.xx, 238.6x
erebrovascular disease, prior
transient ischemic attack, stroke362.34, 430.xx to 438.xx , V12.54C
Appendix B. Patient-reported symptom severity survey scalesSymptom Scale Range (higher
scores= greater
severity)Cut-points:
signiﬁcant symptom
levelepression Quick Inventory of
Depressive
Symptomatology, 16
item (QIDS-SR) [15,16]0–27 QIDS-SR N 5tigue Fatigue Associated with
Depression (FAsD)
Questionnaire, including
total, experience, and
impact scales [17,18]1–5 (items
averaged for each
scale)FAsD Experience
score N 3.2nxiety Generalized Anxiety
Disorder scale, 7 items
(GAD-7) [19]0–21 GAD-7 ≥8somnia Athens Insomnia Scale
(AIS) [20]0–24 AIS ≥6ain Average pain within the
last 24 h using the
single item on the Brief
Pain Inventory (BPI)
Short Form [21]1–10 ≥4 on single item of
BPIcontinued)ppendix B (continued)Symptom Scale Range (higher
scores = greater
severity)Cut-points:
signiﬁcant symptom
leveleavy
alcohol useMeasured by the
Alcohol Consumption
Scale [22]1–11 Cut-point measure
for heavy drinking:
≥5 alcoholic drinks
for males and ≥4
alcoholic drinks for
females in a single
day and/or
pre-period diagnoses
for alcohol-use
disorder or alcohol
dependence (303.xx,
305.0x)Appendix C. Codes for mental health-related utilization and costsCodesedical claimsM
All psychiatric conditions/services
(except bipolar disorder,
schizophrenia, those related to
childhood conditions)ICD-9:
290.xx–316.xx, V40.x, V65.42, 799.81,
780.93, 977.9x excluding [295.0x–295.9x,
299.0x, 299.9x, 302.6x, 307.59, 309.83,
312.1x, 312.2x, 312.81, 312.9x, 313.xx,
314.9x and 315.35]
CPT: 90801–90802, 90804–90809,
90810–90815, 90816–90829,
90845–90857, 90862–90899,
90901–90911, 99510, 4066Fharmacy claims
nxiolytics, Antidepressants, Second
Generation Anti-psychotics,
Hypnotics/Sedatives/AntihistaminesGPI: 57x, 58x, 59x, 60x, 61x,
6250405010x, 6299x, 72100010xGPI = generic product identiﬁer.
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